I have found interesting, to say the least, the career shift of Mr. Gerald "Jerry" Kowalski from the banking business to the biotech industry. The last position he had before he was appointed CEO of OPK Biotech - according to his LinkedIn profile - was as chairman of International Industrial Bank, a russian bank, from 2006 to October 2010. Interestingly, this bank was declared insolvent and bankrupt by a Moscow court in November 2010. It was Mr. Kowalski, then, who was at the helm of this bank when it went bankrupt. Surprisingly, his next move was a career change - to the biotech industry. In just two months he goes from Chairman of a failed bank, to CEO of a biotech company specialized in blood management
Here comes a rather curious finding: According to Wikipaedia, the failed International Industrial Bank was controlled at 100% by a New Zealand-based trust company called OPK Trust Company, belonging to a russian businessman called Sergey Pugachev. Now, remember that Biopure morphed into a company also named OPK, (OPK Biotech, which, in turn, morphed into HbO2).
Seems to me that Mr. Kowalski has been acting as frontman to Mr. Sergey Pugachev's investments under the umbrella of OPK Trust Company. However, according to Wikipaedia, Mr. Sergey Pugachev became at odds with the Russian authorities and as of March 2015, most of his assets had been taken from him by the Russian government and his legal bills had emptied his bank accounts. He lives in exile in London.
Maybe this change of fate for Mr. Pugachev is the explanation as to why OPK Biotech went belly up and resurfaced as Hb2O - still with Mr. Kowalski at the helm, and keeping the intellectual property of Hemopure.
Eden